The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 05, 2019

Filed:

Oct. 13, 2015
Applicant:

University of Maryland, Baltimore, Baltimore, MD (US);

Inventors:

Da-Wei Gong, Olney, MD (US);

Daozhan Yu, Ellicott City, MD (US);

Rongze Yang, Ellicott City, MD (US);

Alan Shuldiner, Baltimore, MD (US);

Ling Chen, Ellicott City, MD (US);

Assignee:

University of Maryland, Baltimore, Baltimore, MD (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61P 9/02 (2006.01); A61P 9/04 (2006.01); A61K 38/16 (2006.01); C07K 14/47 (2006.01); A61K 38/22 (2006.01); A61K 45/06 (2006.01); G01N 33/50 (2006.01); C07K 14/575 (2006.01); G01N 33/68 (2006.01); A61P 9/10 (2006.01); A61P 9/06 (2006.01); A61P 9/00 (2006.01); A61P 9/12 (2006.01); C07K 19/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/22 (2013.01); A61K 38/16 (2013.01); A61K 45/06 (2013.01); A61P 9/00 (2018.01); A61P 9/02 (2018.01); A61P 9/04 (2018.01); A61P 9/06 (2018.01); A61P 9/10 (2018.01); A61P 9/12 (2018.01); C07K 14/47 (2013.01); C07K 14/4722 (2013.01); C07K 14/575 (2013.01); G01N 33/5044 (2013.01); G01N 33/6893 (2013.01); A61K 38/00 (2013.01); C07K 14/4705 (2013.01); C07K 19/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/30 (2013.01); G01N 2800/32 (2013.01); G01N 2800/52 (2013.01);
Abstract

The present invention generally to methods of treating subjects suffering from a cardiac condition or having a risk factor for developing a cardiac condition by administering an ELA peptide or fusion protein to a subject in need. The invention relates to fusion proteins of Fc-ELA-32 and Fc-ELA-21 that exhibit improved properties for use as therapeutic agents, e.g. in the treatment of cardiac conditions. In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.


Find Patent Forward Citations

Loading…